Clinical Trials

Multiple clinical trials investigate the pharmacokinetics, therapeutic response, and clearance of ritalinic acid and its parent compound, primarily evaluating Attention-Deficit/Hyperactivity Disorder (ADHD) and the influence of Carboxylesterase 1 (CES1) genetic variants. Ranging from an unassigned phase to a Phase IV study, these trials maintain recruiting and completed statuses to assess pharmacogenomic markers of stimulant efficacy. Sponsor organizations include academic institutions and health centers such as the University of Calgary, Bispebjerg Hospital, Duke University, and the University of Copenhagen.

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT06221358 Recruiting
Attention-Deficit/ Hyperactivity Disorder (ADHD)
University of Calgary
2024-04-01 --
NCT02147535 Completed
Carboxylesterase 1 (CES1) Genotype|CES1 Activity
Bispebjerg Hospital|The Ministry of Science Technology and Innovation Denmark|Mental Health Centre Sct. Hans (Denmark)|University of Copenhagen|The Leiden Academic Center for Drug Research (LACDR)|Duke University
2014-03 Phase 4

(data from https://clinicaltrials.gov, updated on 2024-05-22)

Check the Ritalinic acid product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

As a major primary metabolite of methylphenidate, ritalinic acid displays negligible binding affinity toward dopamine and norepinephrine transporters compared to its parent compound. Consequently, this lack of target engagement prevents monoaminergic reuptake inhibition and downstream neural excitation, rendering its quantification clinically relevant for evaluating carboxylesterase 1 activity and pharmacokinetic variability in attention-deficit/hyperactivity disorder management.

Appendix RUO and cGMP Quality Standards

Quality Dimension RUO (Research Use Only) cGMP (Current Good Manufacturing Practice)
Clinical Applicability Prohibited in human clinical trials or medical diagnostics. Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status Non-regulated grade; exempt from drug manufacturing laws. Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment Unclassified analytical or research laboratories. Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control Basic purity and activity testing. Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation Basic equipment calibration; no process validation required. Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance Vendor self-declared without required formal QMS. Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact High risk of IND rejection if used as a critical raw material. Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).

Jump to

Note: Technical data last updated: Sep 1, 2026.